Scarica l'app Stockscreener
40.00
2.08%
-0.85
Pre-mercato:
41.09
1.09
+2.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
FY2024 EPS Estimates for RARE Boosted by Cantor Fitzgerald - Defense World
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7%Should You Sell? - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Awards 7,750 Restricted Stock Units to New Non-Executive Officers in Retention Plan - StockTitan
Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
FY2024 EPS Estimates for RARE Increased by Cantor Fitzgerald - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Trimmed by Hennion & Walsh Asset Management Inc. - MarketBeat
Wealth Enhancement Advisory Services LLC Acquires 294 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside - AOL
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 9.1%Here's Why - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $140.00 at Piper Sandler - Defense World
Ultragenyx Pharmaceutical’s (RARE) “Neutral” Rating Reaffirmed at Wedbush - Defense World
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use - MSN
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Ultragenyx Pharmaceutical's (RARE) Neutral Rating Reaffirmed at Wedbush - MarketBeat
Ultragenyx stock gains confidence as FY25 guidance signals 14-20% growth - Investing.com India
JPMorgan Chase & Co. Has $11.84 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for 2024 -January 12, 2025 at 11:00 am EST - Marketscreener.com
Mereo BioPharma Provides Update on Lead Clinical Programs - GlobeNewswire
RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones - GlobeNewswire
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $88.46 Consensus Target Price from Brokerages - Defense World
Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder - MSN
Hypophosphatasia Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma, Alexion - Barchart
Hypophosphatasia Market Predicted to See Upsurge Through 2032, - openPR
Ultragenyx Pharmaceutical's SWOT analysis: rare disease stock poised for growth - Investing.com Australia
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ultragenyx Pharmaceutical's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com South Africa
Ultragenyx Pharmaceutical’s SWOT analysis: rare disease stock poised for growth - Investing.com Nigeria
RBC Capital reiterates Outperform rating on Ultragenyx, optimistic on Osteogenesis Imperfecta drug - Investing.com Nigeria
RBC Capital reiterates Outperform rating on Ultragenyx, optimistic on Osteogenesis Imperfecta drug By Investing.com - Investing.com South Africa
Top 10 startups in Rare Diseases in Bay Area, United States in Jan, 2025 - Tracxn
Political petulance, complacency halt pediatric priority review program - BioCentury
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading 7.2% HigherTime to Buy? - MarketBeat
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Ultragenyx CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
European Commission (EC) Extends the Approval of Evkeeza® - GlobeNewswire
Ultragenyx's Evkeeza Makes Breakthrough: First EU Treatment for Infant HoFH Patients - StockTitan
Principal Financial Group Inc. Has $4.80 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx asks FDA to review gene therapy for Sanfilippo A - Sanfilippo News
Ultragenyx CEO Emil Kakkis sells $495,231 in company stock By Investing.com - Investing.com Canada
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):